Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06869551
Recruiting Phase 3

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551 · tracked via the Priya Life Science Italy tracker
Sponsor
Bristol-Myers Squibb
Phase
Phase 3
Started
2025-03-13
Last updated
2026-08-19

Condition(s) studied

Juvenile Psoriatic Arthritis

Investigational drug(s) / intervention(s)

Deucravacitinib →Placebo

Deucravacitinib: Specified dose on specified days

Placebo: Specified dose on specified days

Study summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Eligibility

Sex
ALL
Min age
5 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria * Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). * Participants must have at least three joints that are affected by arthritis. * Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems. Exclusion Criteria * Participants must not have been diagnosed with JPsA before 5 years of age. * Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA, * Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months. * Other protocol-defined Inclusion/Exclusion criteria apply.

Primary outcome measure(s)

  • Time to first flare during the withdrawal period — From week 16 up to week 42

Trial sites (47)

FacilityCityRegionStatus
Local Institution - 0038 Lancaster California Withdrawn
Local Institution - 0020 Chicago Illinois Withdrawn
Local Institution - 0023 Indianapolis Indiana Withdrawn
Local Institution - 0059 North New Hyde Park New York Withdrawn
Local Institution - 0065 Cincinnati Ohio Withdrawn
Local Institution - 0066 Cleveland Ohio Withdrawn
Local Institution - 0036 Austin Texas Withdrawn
Centro de Oncologia Leonardo Da Vinci - ATO Terapias Fortaleza Ceará Recruiting
Local Institution - 0032 Cuiabá Mato Grosso Withdrawn
Santa Casa de Misericordia de Belo Horizonte Belo Horizonte Minas Gerais Recruiting
Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância Curitiba Paraná Recruiting
Local Institution - 0013 Curitiba Paraná Withdrawn
Hospital Das Clinicas Ufpe Recife Pernambuco Recruiting
Local Institution - 0033 Porto Alegre Rio Grande do Sul Withdrawn
LMK Serviços Médicos S/S Porto Alegre Rio Grande do Sul Recruiting
PSEG- Pesquisa Clínica Vila Clementino São Paulo-SP Recruiting
Local Institution - 0027 Rio de Janeiro Brazil Not Yet Recruiting
Santa Casa Instituto de Pesquisa São Paulo Brazil Recruiting
Local Institution - 0010 São Paulo Brazil Withdrawn
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD Plovdiv Bulgaria Recruiting
Local Institution - 0069 Sofia Bulgaria Not Yet Recruiting
Local Institution - 0062 Sofia Bulgaria Withdrawn
Local Institution - 0074 Beijing Beijing Municipality Not Yet Recruiting
Local Institution - 0049 Beijing Beijing Municipality Not Yet Recruiting
The Children's Hospital of Chongqing Medical University Chongqing Chongqing Municipality Recruiting
Guangzhou Women and Children's Medical Center Guangzhou Guangdong Recruiting
Childrens Hospital of Nanjing Medical University Nanjing Jiangsu Recruiting
The First Hospital of Jilin University Changchun Jilin Recruiting
The Children's Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang Recruiting
Children's Hospital of Fudan University Shanghai China Recruiting
Fakultni nemocnice Olomouc Olomouc Olomouc Region Recruiting
Fakultni nemocnice v Motole Prague Praha 5 Recruiting
Kinderklinik des Uni-Klinikums Erlangen Erlangen Germany Recruiting
Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari Hamburg Germany Recruiting
University of Naples Federico II Naples Campania Recruiting
Azienda Ospedaliera Universitaria Meyer IRCCS Florence Tuscany Recruiting
Local Institution - 0017 San Juan Puerto Rico Withdrawn
Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca Cluj-Napoca Cluj Recruiting
Local Institution - 0048 Iași Iaşi Withdrawn
Sc Medaudio-Optica Srl Râmnicu Vâlcea Vâlcea County Recruiting

+ 7 more sites — see the full list on the official registry below.

More Bristol-Myers Squibb trials in Italy

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease Recruiting
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Starting soon
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis Recruiting

Other trials for the same condition

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Recruiting
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06869551 on ClinicalTrials.gov ↗ ← All trials in Italy